Chief Business Officers: Shedding Light on Biotech’s Dealmakers

02/05/2022 - 5 minutes

In addition to helping patients, biotech companies need to focus on the commercial potential of their work. Stephanie Bewick at Destiny Pharma outlines her experiences of how a Chief Business Officer maximizes their company’s commercial appeal and lands deals in the biotech industry.   

Stephanie Bewick began her career as an academic researcher before spending more than two decades in business development. She has occupied senior positions in biotech companies such as Summit Therapeutics as well as mid-sized pharma firms such as Mayne Pharma. In this time, she has negotiated and closed transactions ranging from the early research phase to late-stage clinical development. 

In 2021, Bewick became the Chief Business Officer (CBO) of Destiny Pharma, a UK biotech focusing on novel medicines for infectious diseases.

What led you to take up the role of CBO?

Becoming a CBO is something that happens after a long time of being in business development. I came out of academia after my PhD, which I think a lot of people do.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member